The Compounding Caution
When a drug breaks sales records and hits shortages, a market for "compounded" versions appears alongside it — often cheaper, sometimes no prescription required, and with a critical difference in oversight. This page explains what compounding is, what the FDA's guidance for these products actually covers and leaves out, and the sourcing rules that separate a legitimate pharmacy service from a supply you should not touch.
What the evidence supports
- Compounded drugs do not undergo the same FDA premarket review as approved brand products.
- FDA guidance and communications during the shortage period have flagged dose-accuracy and purity concerns with compounded GLP-1 products, including reported dosing errors.
- Legitimate compounding requires a patient-specific prescription and is, in practice, a licensed-pharmacy and clinician-supervised activity.
What remains uncertain
- The true scope of the compounding market — online and otherwise — is hard to measure, since much of it sits outside registries.
- How often internet-compounded product contains the dose on the label is not systematically reported; the few documented incidents are the visible tip of an unknown iceberg.
- How the legal landscape shifts as shortages resolve and FDA determinations change is a moving regulatory target.
Evidence last reviewed: August 15, 2026. Conclusions may change as new research is published.
safe sourcing, only
What Compounding Even Is
Compounding is the pharmacist's craft of preparing a medication to order — a different dose, a different form, a version without an allergen. It is a legal and legitimate part of pharmacy practice with a long regulatory history. The problem is not compounding as a practice; it's what happened when weight-loss GLP-1 products hit shortages. When a brand drug is in shortage, FDA guidance can make room for compounding of that product as an interim measure. That is the door through which much of the current market walked — and the door closes differently depending on which product, which shortage, and what the FDA's shortage determinations say at any given moment. The definition that matters for this page is simple: a compounded GLP-1 product is made by a pharmacy off-label from the brand product's recipe, and it has not been through the same approval and inspection process that the brand product went through.
What the FDA Guidance Covers — and Doesn't
The FDA's compounding guidance for these products exists, and describing it honestly means describing its limits. What it does: it lays out the conditions under which compounding a specific product is permitted during a shortage; it sets expectations for facilities doing bulk compounding; and regulators have issued communications flagging real-world problems — notably dosing errors reported with compounded semaglutide, where patients administered a fraction of a milligram's worth of difference with serious consequences. What it doesn't do: it does not approve the product, does not verify that each dose contains what the label claims, and does not guarantee sterile, correctly dosed medicine the way the brand approval pathway is meant to. The regulatory word for the gap is "not subject to premarket review" — the most important sentence on this page. As shortages have eased, FDA determinations have begun to narrow the legal basis for compounding the name-brand products, a moving target that makes "is this even legal right now?" a genuinely current question.
The Differences That Matter
| Dimension | Approved brand product | Legitimate compound | Unverified source |
|---|---|---|---|
| 🏭 How it's made | FDA-approved facility, inspected | Licensed pharmacy, patient-specific Rx | Unknown facility, often none |
| ⚖️ Oversight | Full premarket review | State pharmacy + FDA guidance conditions | Effectively none you can verify |
| 💧 What the label guarantees | Confirmed dose and purity | Pharmacy's own quality controls | Nothing verifiable |
| 👨⚕️ Who's in the loop | Prescribing clinician | Prescribing clinician | Often nobody |
⚠️ Strong warning: compounding is guidance-permitted, not FDA-approved
The single most important distinction in this entire page is that a compounded GLP-1 product is not the same thing as the approved product — it has not been through FDA premarket review, and regulators have explicitly flagged dose-accuracy and purity concerns in this exact category, including serious reported dosing errors with compounded semaglutide. No knowledge of chemistry makes an internet bottle verifiable. If a prescriber ever raises compounding with you, treat it as a question for a licensed pharmacy and a prescribing clinician — never something to solve on a website.
The Safe-Sourcing Rules
- 🧾 Prescription first, always. No prescription, no legitimate path. A product sold "without a prescription" has removed the one gate that makes any of this supervised medicine.
- 🏥 Name the pharmacy. A verifiable licensed pharmacy that can answer questions about compounding conditions, sterility practices, and sourcing is the minimum floor. If you can't identify the licensed pharmacy behind the product, that is the answer.
- 👨⚕️ Keep the clinician in it. Whoever prescribes should know exactly what product you're taking. A prescriber cannot monitor a product they don't know exists.
- 💲 Price is the tell, not the deal. Deeply discounted GLP-1 products are deep discounts on the thing that costs the most — the oversight. Cheap is not a feature of this medicine; it's a flag.
- 🔄 Ask why. If the brand product is available and covered, the honest question for a compounding offer is "why not the approved product?" — and the answer should come from a clinician, not an advertisement.
The True Cost of the "Discount"
The economics of the compounding market deserve one honest paragraph, because price is how the pitch usually arrives. The discount you're being offered is a measure of what was removed — and what was removed is not the active ingredient, it is the oversight. The brand product's price pays for development, manufacturing controls, sterility assurance, consistent potency, and a recall-and-monitoring system. A compounded copy priced at a fraction of that has paid for none of those things in a way you can verify from the label. For most purchases, cheaper means the same product at a better price. For prescription medicine sourced from an unverifiable channel, cheaper means a different product-package — same idea, unbounded risk. The parent page's framing is worth repeating: compounded versions sit outside the standard regulatory review of the brand products.
The Dos and Don'ts of the Conversation
- 🧾 Do ask for the specifics. Which pharmacy, which salt form, which stabilizers, which sterility assurance? A legitimate pharmacy answers these directly; a checkout page does not.
- 👨⚕️ Do loop in the prescriber. If the offer comes from anyone other than the person managing your prescription, that is not a supplier — it's a red flag wearing a discount.
- 🚫 Don't let urgency make the decision. "Limited supply, act now" is a sales pattern; a clinical decision made on that rhythm is a decision made without one of the parties who should be in it.
- 🔁 Don't assume "same as before." A different source is a different product, even if it shares a molecule name. Switching sources deserves the same conversation as any medication change.
The Bottom-Line Question to Ask
Every sourcing decision on this page compresses into one question, best put to a prescriber or a licensed pharmacist: what exactly am I taking, who made it, and who is watching the dose? If any of the three answers is fuzzy — the source is a website, the maker is unnamed, or nobody is monitoring — then the product fails on its own terms. This page's job is not to enumerate every bad actor; it is to make the verification standard so simple that you can apply it in thirty seconds. The stakes also compound in reverse: the side-effect, muscle, and regain questions from the rest of the GLP-1 era topic all become unanswerable if you can't trust the dose you took in the first place.
Questions, Answered Briefly
- ⚗️ Is compounded semaglutide the same medicine? No. The active molecule is similar, but the product has not gone through the same review, and regulators have flagged real dosing errors in this exact category. "Same molecule" and "same medicine" are different sentences.
- 💲 Is it ever the reasonable choice? In legitimate practice, compounding can serve a specific patient when the brand form is wrong — a dose, an allergen, a shortage. That is a licensed-pharmacy, clinician-supervised conversation, not an online deal.
- 🚨 Isn't the cheap online version "basically the same"? The price difference is a purchase of the review, testing, and supervision that make the product trustworthy. The catastrophic dosing-error reports are the documented cost of skipping them.
- 🧪 If I'm already on a compound, what now? Bring the vial, the pharmacy name, and the label to your clinician. The move is verification and monitoring — not shame, and not silence.
The Bottom Line
- Compounded GLP-1 products are not the approved product — they skip the premarket review, and regulators have flagged real dose-accuracy and purity problems in this exact category.
- Compounding is legitimate only in credentialed form — a licensed pharmacy, a valid prescription, and a clinician who knows what you're taking.
- The verification standard is thirty seconds long — what exactly am I taking, who made it, and who's watching the dose? Any fuzzy answer is a no.
- The market is a moving regulatory target — shortage determinations shift, so "is this even permitted right now" is a live question, and it's a clinician's to answer, not a checkout page's.
Related Topics
- U.S. Food and Drug Administration, compounding guidance and drug-safety communications covering GLP-1 products during shortage periods (2024–2025)
- Wilding et al., "Once-weekly semaglutide in adults with overweight or obesity," New England Journal of Medicine (2021)
- Jastreboff et al., "Tirzepatide once weekly for the treatment of obesity," New England Journal of Medicine (2022)
- Rubino et al., "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4)," JAMA (2021)